As if Big Pharma didn't have enough problems ...My comment is more about the growing value of ATE over the next two years as Big Pharma is searching for revenue replacement. Now, recreational maraijuana is also getting in the way of their revenue growth.
A Cornell University Study ...
Researchers looked at Medicaid prescription data between 2011 and 2019 and found there was a decline in drug usage among Medicaid enrollees with access to recreational marijuana. We’re talking drugs to treat pain, depression, anxiety or help with sleeping, you know, the kind with television commercials. The report, published in the Health Economics journal on Good Friday (do with that what you will), said that its “results suggest substitution away from prescription drugs and potential cost savings for state Medicaid programs.” So ... my list of items that may likely make ATE look more desirable for Big Pharma negotiations include ...
1. more than doubling OTENA IP from 7 yrs to 15+ by the time OTENA comes to market
2. market size potental of >$25B (OTENA - acute) to >$55B (OTENA - acute & chronic)
3. Big Pharma's sales losses to recreational marajuana and similar (over time) - further review required re. the actual sales losses we might be talking about
4. H3R Bill in the USA - cutting into some Big Pharma revenues
5. Opioid litigation costs affecting profitability for some while leading to extinction for others
6. FDA/CDC push away from opioids where/when possible
7. Patent cliff affecting various Big Pharma companies out to 2030 (and beyond)
8. Bad calls made by some Big Pharmas - Bayer /Round Up - Biogen/ADUHELM
----------
Lots of reasons to think our very large markets would be desirable for some Big Pharms.
Just some thoughts as 2022 gets going !!!